<DOC>
	<DOCNO>NCT00125736</DOCNO>
	<brief_summary>The purpose study investigate efficacy safety combination use E0671 Rabeprazole Sodium patient gastric ulcer .</brief_summary>
	<brief_title>A Double-blind , Comparative Study Patients With Gastric Ulcer Evaluate Efficacy Combination Use E0671 Rabeprazole Sodium</brief_title>
	<detailed_description>The efficacy safety E0671 combination Rabeprazole Sodium ( i.e. , 10 mg/day rabeprazole sodium 150 mg/day E0671 ) investigate patient gastric ulcer multicenter , randomize , double-blind , parallel-group comparative study use placebo control group ( 10 mg/day rabeprazole sodium placebo E0671 ) .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Stomach Ulcer</mesh_term>
	<mesh_term>Rabeprazole</mesh_term>
	<criteria>Inclusion criterion : 1 . Patients gastric ulcer ( A1and A2stage ) 2 . Patients gastric ulcer meet follow item . Gender treatment class ( inpatient outpatient ) ask . Patients endoscopically diagnose A1 A2stage ulcer ( Sakita/Miwa classification ) . Patients young 20 year age time obtain informed consent . Patients meet following condition : H. pylorinegative H. pyloripositive require eradication therapy H. pyloripositive unsuccessful eradication 3 . Patients give full explanation study objective design , able give prior consent study participation . Exclusion criterion : 1 . Patients complication duodenal ulcer ( exclude cicatrix ) . 2 . Patients reflux esophagitis 3 . Patients acute gastric mucosal lesion ( AGML ) . 4 . Patients NSAIDinduced ulcer . 5 . Patients linear ulcer . 6 . Patients ulcer injured endoscopy . 7 . Patients underwent gastrectomy vagal nerve resection . 8 . Patients applied pharmacotherapy , i.e. , perforation , pyloric stenosis , major bleeding ( expose blood vessel base ulcer ) , etc . 9 . Patients receive proton pump inhibitor ( PPI ) and/or teprenone preparation ( ) within 1 week prior study administration . 10 . Patients serious cardiovascular disease ( e.g. , angina pectoris , heart failure , acute myocardial ischemia , severe tachyarrhythmia ) , serious hematological disorder ( e.g. , aplastic anemia ) , serious renal disorder ( e.g. , acute , chronic renal failure ) , serious hepatic disorder ( e.g. , cirrhosis , severe hepatitis ) , serious pancreatic disorder ( e.g. , severe pancreatitis ) , serious psychoneurosis ( e.g. , schizophrenia , alcoholic dependency , drug dependency , severe depression ) , cancer . 11 . Patients current history drug allergy teprenone preparation ( ) . 12 . Patients current history drug allergy PPI . 13 . Patients require antacid ( ) contain digoxin aluminum hydroxide/magnesium hydroxide suspect exert drug interaction rabeprazole sodium .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
</DOC>